MedPath

Lenacapavir

Generic Name
Lenacapavir
Brand Names
Sunlenca
Drug Type
Small Molecule
Chemical Formula
C39H32ClF10N7O5S2
CAS Number
2189684-44-2
Unique Ingredient Identifier
A9A0O6FB4H
Background

HIV/AIDS remains an area of concern despite the introduction of numerous successful therapies, mainly due to the emergence of multidrug resistance and patient difficulty in adhering to treatment regimens. Lenacapavir is a first-in-class capsid inhibitor that demonstrates picomolar HIV-1 inhibition as a monotherapy in vitro, little to no cross-resistance with existing antiretroviral agents, and extended pharmacokinetics with subcutaneous dosing.

Lenacapavir was first globally approved on August 22, 2022 by the European Commission to treat adults with multi-drug resistant HIV infection. On December 22, 2022, it was also approved by the FDA.

Indication

Lenacapavir, in combination with other antiretroviral(s), is indicated for the treatment of multidrug-resistant human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults who are experiencing a failure of their current antiretroviral regimen due to resistance, intolerance, or safety considerations.

Associated Conditions
Multidrug resistant HIV-1 infection
Associated Therapies
-
Clinical Trials
Related News
fiercebiotech.com
·

Merck's HIV combo treatment meets the bar for viral suppression in pair of phase 3 studies

Merck & Co.'s islatravir, combined with doravirine, met primary efficacy goals in phase 3 trials for HIV-1 treatment, showing non-inferiority to existing therapies but not superiority in a Biktarvy comparison. Merck plans to advance islatravir combinations for HIV treatment, with detailed findings to be presented and submitted to regulators.
healthpolicy-watch.news
·

Pepfar And Global Fund Target Rollout Of HIV Prevention Injectable

Lenacapavir, a twice-yearly HIV injection, could reach 2 million people in 3 years through Global Fund and PEPFAR, pending FDA, national, and WHO approvals. Clinical trials showed 99%+ success rate in preventing HIV. Gilead has signed voluntary licensing agreements for generic versions in 120 low- and middle-income countries. Global regulatory filings for PrEP are set to begin by end of 2024.
finance.yahoo.com
·

4 Big Drug Stocks That May Continue to Outperform in 2025

The drug and biotech sector experienced a strong first half of 2024 with a 19.3% rise in the Zacks Large Cap Pharmaceuticals industry, driven by M&A, earnings, and regulatory successes. However, a downturn in the second half due to disappointing sales, guidance cuts, and pipeline setbacks led to an 11% decline. Despite this, Gilead, Eli Lilly, Vertex Pharmaceuticals, and AbbVie outperformed, with growth drivers like Gilead's HIV therapies, Lilly's tirzepatide medicines, Vertex's CF treatments, and AbbVie's new immunology drugs poised to sustain momentum into 2025.
ctvnews.ca
·

A twice-yearly shot could help end AIDS. But will it get to everyone who needs it?

A twice-yearly HIV vaccine, lenacapavir, has shown 100% effectiveness in preventing HIV in women and nearly as well in men. Gilead plans to allow generic versions in 120 high-HIV countries but excludes Latin America, where rates are increasing. UNAIDS' Winnie Byanyima calls the vaccine 'unprecedented' and crucial for ending the epidemic. Gilead aims to expand access globally, but concerns remain over exclusion of Latin American countries, where stigma and rising HIV rates pose challenges.
unb.com.bd
·

A twice-yearly shot could help end AIDS - Bangladesh

Lenacapavir, a new HIV prevention shot, demonstrated near-perfect results in clinical trials, requiring administration only twice a year. Gilead plans to provide affordable generic versions in 120 low-income countries but excludes most Latin American nations, sparking criticism. Advocacy groups urge inclusion and affordable access, highlighting the drug's potential to curb rising infection rates and stigma.
pharmaceutical-technology.com
·

PrEP therapies utter new hope in HIV preventive landscape as vaccine failures amass

Research in HIV is shifting towards PrEP therapies due to vaccine failures; Dr. Jonathan Weber highlights the challenges in HIV vaccine development, including lack of animal models and natural immunity, and predicts future investment will focus on long-acting PrEP due to its cost-effectiveness and transformative potential in preventing transmission.
drugs.com
·

Twice-Yearly Injection 96% Effective in Preventing HIV Infection

Twice-yearly injection of Sunlenca (lenacapavir) reduces HIV infection risk by 96%, outperforming daily oral PrEP pills like Truvada, according to a clinical trial in the New England Journal of Medicine. The injection, administered every six months, offers significant advantages for those with limited access to daily medication or difficulty adhering to a daily regimen.
clinicaltrialsarena.com
·

Gilead and MSD to advance once-weekly HIV treatment to Phase III

Gilead and MSD advance their once-weekly HIV treatment to Phase II trials after a 48-week study showed 94.2% of patients maintained viral loads below 50 copies m/L. The treatment combines MSD’s islatravir with Gilead’s lenacapavir, offering a long-acting alternative to daily HIV medications like Gilead’s Biktarvy.

Related Clinical Trials:

Study Evaluating the Safety and Efficacy of Islatravir in Combination With Lenacapavir in Virologically Suppressed People With HIV
Pre-Exposure Prophylaxis Study of Lenacapavir and Emtricitabine/Tenofovir Alafenamide in Adolescent Girls and Young Women at Risk of HIV Infection
Study of Lenacapavir for HIV Pre-Exposure Prophylaxis in People Who Are at Risk for HIV Infection
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy